![PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) | Markets Insider PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) | Markets Insider](https://mma.prnewswire.com/media/753414/Lamira_Nebulizer_System.jpg)
PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) | Markets Insider
![Magnair™ an eFlow® Closed System Nebulizer together with Sunovion's Lonhala™ is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD) Magnair™ an eFlow® Closed System Nebulizer together with Sunovion's Lonhala™ is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)](https://mma.prnewswire.com/media/616445/PARI_Pharma_Lonhala_Magnair_Inhalation_Solution.jpg?p=twitter)
Magnair™ an eFlow® Closed System Nebulizer together with Sunovion's Lonhala™ is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)
Getting to know CAYSTON What is CAYSTON? Who should not take CAYSTON? What you should tell your doctor before taking CAYSTON How
Guidance on the Use of eFlow Nebulizers (Altera® and Trio®) April 6, 2010 David E. Geller, MD and Kenneth C. Kesser, RRT Nemou
![LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension) LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)](https://mma.prnewswire.com/media/1472397/eFlow_Partnering_eBase_Controller_Lamira.jpg?p=facebook)
LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)
Getting to know CAYSTON What is CAYSTON? Who should not take CAYSTON? What you should tell your doctor before taking CAYSTON How
![In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution | Journal of Aerosol Medicine and Pulmonary Drug Delivery In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution | Journal of Aerosol Medicine and Pulmonary Drug Delivery](https://www.liebertpub.com/cms/10.1089/jamp.2017.1384/asset/images/medium/figure1.gif)